Skip to main content
. 2008 Dec 2;40(3):13. doi: 10.1051/vetres:2008051

Table IV.

Summary table to show sub-clinical infection (as measured by FMDV isolation from oropharyngeal fluids) and persistence in cattle following vaccination with FMD vaccines formulated for emergency use and subsequent challenge with FMDV.

Vaccine Challenge Days
vaccinated
before exposure		 Virus isolation (or viral RNA recovery) from oropharyngeal
fluids weeks post challenge
 NSABa Ref.
1 2 3 4 5 6 7 8 9 10
O1 Lausanne
4.1 μg/dose
Oil		 Homologous indirect aerosol from
3 infectious pigs for 1 h		 21 3/3b 3/3 3/3 1/3 1/3 0/3 3/3 1/2 3/3 2/3 [25]
16 0/2 3/3 1/3 1/3 0/3 0/3 0/3 0/3 0/3 0/3
12 3/3 2/2 3/3 2/3 2/3 1/2 1/3 1/3 2/3 2/3
8 2/3 3/3 3/3 1/3 3/3 1/3 2/3 3/3 3/3 3/3
4 2/2 2/2 2/2 2/2 2/2 2/2 2/2 0/2 2/2 2/2
 
O1 Lausanne
4.1 μg/dose
Aqueous		 21 0/2 1/2 2/2 0/2 0/2 0/2 0/2 0/2 0/2 1/2
16 2/3 3/3 3/3 2/3 3/3 1/2 1/3 1/3 2/3 1/3
12 1/3 3/3 3/3 1/3 1/3 1/3 3/3 1/3 1/3 1/3
8 2/3 3/3 3/3 2/3 2/3 2/3 1/2 2/3 2/3 2/3
4 1/2 1/1 2/2 1/2 1/2 1/2 1/2 0/0 1/2 1/1
0 1/1 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 1/1
cC1 Oberbayern
1.9 μg/dose
oil		 Homologous indirect aerosol from
3 infectious pigs for 1 h		 21 0/3 0/3 0/3 0/3 0/3 0/3 0/3 1/3 0/3 0/3 [25]
16 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
12 1/3 1/3 3/3 1/3 0/3 0/3 0/2 0/2 0/2 0/2
8 1/3 0/3 1/3 0/3 0/3 0/3 1/3 1/3 0/3 0/3
4 0/2 0/2 1/2 0/2 0/2 0/2 0/2 0/2 0/1 0/2
 
d C1 Oberbayern
1.9 μg/dose
Aqueous		 21 1/3 0/3 0/3 0/3 0/3 0/3 0/3 0/1 0/3 0/3
16 0/3 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
12 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
8 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
4 0/2 0/2 1/2 1/2 1/2 0/2 0/2 0/2 0/2 0/2
0 1/2 2/2 2/2 2/2 2/2 0/2 1/2 0/2 1/2 0/2
Asia 1 India 8/79
4.8 μg/dose
Oil		 Homologous indirect aerosol from
3 infectious pigs for 1 h		 12 NA 1/2 See
footnote 1
8 3/3 2/3
4 2/2 2/2
3 NA 1/3
2 3/3 3/3
 
Asia 1 India 8/79
4.8 μg/dose
Aqueous		 12 0/2 0/2
8 NA 1/3
4 3/3 3/3
3 NA 2/3
2 NA 3/3
0 2/2 ND
O1 Manisa
? (18 PD50)
1× payload
Oil		 Semi-heterologous direct contact
with 5 infectious cattle for 5 days		 21 10/20
(9/20)d 		8/20
(7/20)		 9/20
(8/20)		 1/20
(9/20)		 7/20e [21]
0 5/5
(5/5)		 2/5
(2/5)		 3/5
(2/5)		 0/5
(1/5)		 5/5
 
O1 Manisa
? (18 PD50)
10× payload
Oil		 Semi-heterologous direct contact
with 5 infectious cattle for 5 days		 21 10/18
(8/17)		 1/19
(1/19)		 3/20
(3/20)		 2/19
(1/19)		 5/20 [22]
0 4/5
(5/5)		 1/4
(2/4)		 2/4
(1/4)		 2/4
(2/4)		 5/5
O1 Manisa
? (18 PD50)
1× payload
Oil		 Semi-heterologous direct contact
with 5 infectious cattle for 5 days		 10 16/20
(15/20)		 9/20
(9/20)		 12/20
(8/20)		 9/20
(9/20)		 16/20 [23]
0 5/5
(3/5)		 1/5
(1/5)		 2/5
(2/5)		 2/5
(2/5)		 5/5
O1 Manisa
? (18 PD50)
10× payload
Oil		 Semi-heterologous direct contact
with 5 infectious cattle for 5 days		 10 16/19
(14/19)		 7/15
(7/16)		 8/17
(7/17)		 6/16
(9/16)		 12/17
0 5/5
(5/5)		 0/5
(0/5)		 0/5
(0/5)		 0/5
(2/4)		 5/5
a

Non structural antibody

b

number of animals from which FMDV recovered/total number of animals

c

cattle previously used for O1 Lausanne vaccine experiment

d

number of animals from which viral RNA recovered/total number of animals

e

number of animals which seroconverted to non-structural proteins/total number of animals.